Literature DB >> 10515302

Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity.

D J Sanger1, G Griebel, G Perrault, Y Claustre, H Schoemaker.   

Abstract

The GABA(A) receptor complex contains a number of binding sites at which a variety of psychotropic drugs, including benzodiazepines, barbiturates, and some neurosteroids, act to potentiate or inhibit the effect of the transmitter. Many studies have reported that these drugs can produce discriminative stimulus actions, but the cueing effects of compounds acting at different sites to enhance the effects of GABA are not identical. The discriminative stimulus effects of benzodiazepines have been analyzed in detail, and there is also a great deal of information available on the effects of nonbenzodiazepine compounds acting at BZ(omega) recognition sites, which form part of the GABA(A) receptor complex. Of particular interest are compounds with selectivity for the BZ1(omega1) receptor subtype including zolpidem, zaleplon, and CI 218,872. BZ1(omega1)-selective drugs substitute for the discriminative stimulus produced by chlordiazepoxide only partially and at sedative doses. This is consistent with the view that sedative effects of BZ(omega) receptor agonists are mediated by the BZ1(omega1) receptor subtype, whereas the discriminative stimulus produced by chlordiazepoxide may be produced by activity at the BZ2(omega2) subtype. Analysis of this hypothesis is complicated by the variety of levels of intrinsic activity shown by different drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515302     DOI: 10.1016/s0091-3057(99)00081-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Lorazepam should no longer be used as a prototypical benzodiazepine.

Authors:  S Pompéia; O F A Bueno; S Tufik
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

2.  Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects.

Authors:  Barak W Gunter; Sherman A Jones; Ian A Paul; Donna M Platt; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2016-06-29       Impact factor: 4.530

Review 3.  Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?

Authors:  Rosella Ciurleo; Placido Bramanti; Rocco Salvatore Calabrò
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 5.  Benefit-risk assessment of zaleplon in the treatment of insomnia.

Authors:  Joseph Barbera; Colin Shapiro
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Neurosteroid influences on sensitivity to ethanol.

Authors:  Christa M Helms; David J Rossi; Kathleen A Grant
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-31       Impact factor: 5.555

7.  GABA(A) receptor α subunits differentially contribute to diazepam tolerance after chronic treatment.

Authors:  Christiaan H Vinkers; Ruud van Oorschot; Elsebet Ø Nielsen; James M Cook; Henrik H Hansen; Lucianne Groenink; Berend Olivier; Naheed R Mirza
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

8.  Lack of generalisation between the GABAA receptor agonist, gaboxadol, and allosteric modulators of the benzodiazepine binding site in the rat drug discrimination procedure.

Authors:  Signe Michelsen; Connie Sánchez; Bjarke Ebert
Journal:  Psychopharmacology (Berl)       Date:  2007-03-15       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.